Antigen Preparation
Expressed in prokaryotic or eukaryotic systems to give high-purity, correctly folded recombinant protein for antibody screening, immunisation and assay development.
Expressed in prokaryotic or eukaryotic systems, the recombinant protein is high-purity and correctly folded for antibody screening, immunisation and assay development.
We provide one-stop custom antigens across every molecule type for antibody drug development, vaccine research and in vitro diagnostics. Four core platforms — recombinant protein, nanodisc, virus-like particle (VLP) and mRNA — address the specific bottlenecks each molecule type brings to antigen preparation.
Whether you need an immunogen for animal immunisation, a detection antigen for antibody screening or a functional antigen for proof of concept, we match the expression system and presentation format to the molecule's structure and its application — delivering from sequence to functional antigen quickly.
Enquire now →
Recombinant protein, nanodisc, VLP and mRNA presentation systems combined — covering the full antigen spectrum from transmembrane proteins to small molecules.
Nanodiscs mimic the native lipid environment, VLPs self-assemble into viral geometry, and mRNA is translated and folded in vivo.
Parallel workstreams with real-time milestone updates cut average delivery time by more than 30%.
Multiple tags, modifications and formulations supported, from research grade through pilot scale.
Four stages. Whether the antigen is an immunogen for animals, a detection antigen for screening or a functional antigen for proof of concept, the expression system is matched to the molecule's structure; outputs and acceptance criteria are in the specifications below.
The optimal expression system and presentation format are matched to the molecule and its application
Codon optimisation, gene synthesis and vector construction — sequence 100% correct
Pilot screening, fermentation or cell culture, then affinity/ion-exchange/size-exclusion chromatography to ≥85% purity
SDS-PAGE, Western blot, SEC-HPLC and BCA quantification, delivered as lyophilised powder or liquid with a COA
Construction takes 5–7 working days, expression and purification 10–15, and QC with formulation 3–5 — roughly 18–27 working days in total.
Recombinant protein, nanodisc, VLP and mRNA platforms work together to address the real bottlenecks in antigen preparation: complex membrane proteins that lose their native conformation, small molecules and short peptides with weak immunogenicity, conformational epitopes that need intact viral particles, and programmes under time pressure. Parallel execution with milestone feedback cuts average delivery time by more than 30%.
Deliverables, acceptance criteria and timelines by experimental stage. The staging differs from the process above: the process shows how a project runs, while this table is the acceptance basis written into the contract.
| Stage | Scope | Deliverables | Standards | Timeline |
|---|---|---|---|---|
| Recombinant protein antigen platform | ||||
| Construct design | Codon optimisation, gene synthesis and expression vector construction | Sequence-verified plasmid and strain | Sequence 100% correct | 5-7 business days |
| Expression and purification | Pilot expression screening → fermentation or cell culture → affinity, ion-exchange and size-exclusion chromatography | Purified protein solution | Purity ≥85% | 10-15 business days |
| QC & formulation | SDS-PAGE, Western blot, SEC-HPLC and BCA quantification | CoA, raw spectra, lyophilised powder or liquid | Batch-to-batch consistency confirmed, sterility test passed | 3-5 business days |
SDS-PAGE — no non-specific bands or degradation fragments, with purity above 95% throughout.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
